Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Ironwood Pharma (IRWD) Tops Q3 EPS by 2c; Initiates Phase III Trial of 72 mcg Linaclotide
November 4, 2014 4:53 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $16.2 million versus the consensus estimate of $21.2 million.
The company also announced today the initiation of a Phase III clinical... More



